The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).
 
Scott Joseph Antonia
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck
 
Jose A. Lopez-Martin
Stock and Other Ownership Interests - PharmaMar; Zeltia
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; MSD; NanoString Technologies; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PharmaMar
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis
 
Johanna C. Bendell
No Relationships to Disclose
 
Patrick Alexander Ott
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca; Bristol-Myers Squibb; Merck
 
Matthew H. Taylor
Honoraria - Eisai
Consulting or Advisory Role - Eisai; Onyx
 
Joseph Paul Eder
Honoraria - Merck
 
Dirk Jäger
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Roche
 
Dung T. Le
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck
 
Filippo G. De Braud
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Novartis; SERVIER
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Genentech/Roche; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Genentech/Roche; Novartis
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Onyx (Inst); Precision Biologics (Inst)
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech; Ventana Medical Systems
Research Funding - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst)
 
Leora Horn
Honoraria - Biodesix
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Merck; Puma Biotechnology; Xcovery
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst)
 
Asim Amin
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Speakers' Bureau - Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Argos Therapeutics; Bristol-Myers Squibb; Merck; Prometheus
 
Rathi Narayana Pillai
No Relationships to Disclose
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Baxter (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Celgene
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); e-Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); Roche (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene
 
Christopher T. Harbison
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Chen-Sheng Lin
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Marina Tschaika
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
Other Relationship - Pierre Fabre